Use of Intravitreal Bevacizumab in a 9-Year-Old Child with Choroidal Neovascularization Associated with Autosomal Recessive Bestrophinopathy

Rumana N. HussainLeicester Royal Infirmary, Medical Retina Department, University Hospitals of Leicester, UKCorrespondence[email protected]

Fatema L. ShahidLeicester Royal Infirmary, Medical Retina Department, University Hospitals of Leicester, UK

Theodoros EmpeslidisLeicester Royal Infirmary, Medical Retina Department, University Hospitals of Leicester, UK

Soon Wai Ch’ngLeicester Royal Infirmary, Medical Retina Department, University Hospitals of Leicester, UK

References

Boon CJ, Jeroen Klevering B, et al. The spectrum of ocular phenotypes caused by mutations in the BEST1 gene. Prog Retin Eye Res 2009;28:187–205
PubMed Web of Science ®Google Scholar
Burgess R, Millar ID, Leroy BP, et al. Biallelic mutation of BEST1 causes a distinct retinopathy in humans. Am J Hum Genet 2008;82:19–31
PubMed Web of Science ®Google Scholar
Andrade RE, Farah ME, Costa RA. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in Best disease. Am J Ophthalmol 2003;136:1179–1181
PubMed Web of Science ®Google Scholar
Cakir M, Cekic O, Yilmaz OF. Intravitreal bevacizumab and triamcinolone treatment for choroidal neovascularization in Best disease. J AAPOS 2009;13:94–96
PubMed Web of Science ®Google Scholar
Chhablani J, Jalali S. Intravitreal bevacizumab for choroidal neovascularization secondary to Best vitelliform macular dystrophy in a 6-year-old child. Eur J Ophthalmol 2012;22:677–679
PubMed Web of Science ®Google Scholar
Mandal S, Sinha S, Venkatesh P, Vashisht N. Intravitreal bevacizumab in choroidal neovascularization associated with Best’s vitelliform dystrophy. Indian J Ophthalmol 2011;59:262–263
PubMed Web of Science ®Google Scholar
Cennamo G, Cesarano I, Vecchio EC, Reibaldi M, Crecchio GD. Functional and anatomic changes in bilateral choroidal neovascularization associated with vitelliform macular dystrophy after intravitreal bevacizumab. J Ocul Pharmacol Ther 2012;28:643--646
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Use of Intravitreal Bevacizumab in a 9-Year-Old Child with Choroidal Neovascularization Associated with Autosomal Recessive Bestrophinopathy

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Use of Intravitreal Bevacizumab in a 9-Year-Old Child with Choroidal Neovascularization Associated with Autosomal Recessive Bestrophinopathy

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date